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Acute Coronary Syndromes: Current Treatment guidelines and Updates 
by Bernard Lau, Pharm.D. Candidate 2014, Michael Lee, Pharm.D. Candidate 2014, Thien Tran, Pharm.D. Candidate 2014, Laura 
Tsu, Pharm.D, Midwestern University College of Pharmacy-Glendale
goal: 
This home-study CPE activity has been 
developed to educate pharmacists on acute 
coronary syndrome (ACS) and its medical 
management.
Objectives: At the conclusion of this CPE 
activity, successful participants should be 
able to:
1. Identify the type of ACS (STEMI, 
NSTEMI, or UA) based on imaging 
and laboratory values. 
2. List the recommendations for 
emergency department management 
for ACS. 
3. Assess the eligibility of patients 
(STEMI or NSTEMI/UA) for PCI or 
fibrinolytic therapy. 
4. Develop an appropriate 
pharmacotherapy treatment plan in 
patients admitted into hospital with 
ACS (STEMI or NSTEMI/UA). 
5. Discuss the medication management 
for discharge in the patient with ACS. 
Introduction
Cardiovascular disease (CVD) is a 
major leading cause of death worldwide.  
Acute coronary syndromes (ACS) 
make up the majority of CVD related 
mortalities, with more than 1.2 million 
Americans suffering from some sort of 
ACS every year.1  ACS, a result of having 
coronary heart disease, is very costly to 
health care and the economy, with direct 
and indirect costs totaling more than  
$177 billion in 2010.
Etiology
ACS is a result of occlusion and 
rupturing of atherosclerotic plaques in the 
vasculature of the heart.1  Atherosclerosis 
is a narrowing of the arteries that involves 
excess cholesterol and inflammation.  The 
initial stage of this disease begins with 
an atherosclerotic plaque, or atheroma.  
These plaques normally occur in humans 
starting in the adolescent years.  They 
are composed of macrophages that have 
taken up oxidized low density lipoproteins 
(LDL).  Over time, these macrophages 
become foam cells, which subsequently 
become calcified as they become older and 
less metabolically active.  The calcified 
plaque causes the artery to become stiff, 
which induces more stress on the arteries 
when blood flows through them as they 
are less compliant.  As a result, gene 
regulation is altered and the endothelial 
cells lining the blood vessels decrease 
their production of nitric oxide, a potent 
endogenous vasodilator.  The alteration 
in gene regulation also causes an increase 
in the rate of oxidation of LDL and 
enables them to enter the arterial wall.  
Monocytes also become more adhesive 
to the arterial wall, which causes smooth 
cell proliferation and the release of local 
vasoconstrictors and prothrombotic 
substances into the blood, resulting in an 
inflammatory response.
Pathophysiology
The leading cause of ACS in most 
patients is rupture of an unstable 
atherosclerotic plaque with subsequent 
thrombus development resulting in the 
limitation or interruption of coronary 
blood flow.1  In contrast to a stable plaque, 
an unstable plaque has an irregular shape, 
a thin fibrous cap, minimal amount of 
smooth muscle cells and a large lipid core 
that is highly populated with inflammatory 
cells such as macrophages and 
lymphocytes.  These inflammatory cells 
release proteolytic enzymes and cause 
the thinning of the fibrous cap resulting 
in a plaque that is more susceptible to 
tear under constant shear stress.  It is 
also noted that plaques that occlude less 
than 50% of the diameter of the coronary 
artery are more likely to rupture than 
those with a higher degree of occlusion.  
Following plaque rupture, tissue factor and 
subendothelial collagen are exposed to the 
blood components at the site of rupture, 
leading to platelet adhesion and activation. 
Activated platelets release thromboxane 
A2, adenosine diphosphate (ADP), and 
other vasoactive and prothrombotic 
substances that further intensify 
platelet recruitment and aggregation.  
Additionally, during platelet activation, 
ADP binds to the P2Y12 receptors and 
induces a conformational change in the 
glycoprotein (GP) IIb/IIIa receptors 
located on the surface of platelets, thereby 
facilitating the binding of fibrinogens 
responsible for cross-linking other 
platelets to form a preliminary clot.  At 
the same time, the extrinsic coagulation 
cascade pathway is also activated by the 
exposed tissue elements at the site of 
injury.  Thrombin (factor IIa), the final 
product of this cascade and a potent 
platelet aggregation agonist, stabilizes 
the cross-linked platelets by converting 
the fibrinogen bridges to fibrin, thus 
trapping the red blood cells to form a 
stable clot.  Other clotting factors also 
contribute to clot extension by gathering 
on the anionic surface of activated 
platelets and promoting more thrombin 
production.  When a thrombus causes 
complete occlusion of the coronary artery 
and interruption of coronary blood flow, 
myocardial ischemia occurs and may 
lead to necrosis of myocardial tissues 
(i.e.  myocardial infarction or MI).  Most 
ACS cases involve only one ruptured 
atherosclerotic plaque in a major coronary 
artery; however, multiple ruptured plaques 
can occur and may affect more than 
one coronary artery.  ACS patients with 
multiple coronary artery involvement 
usually have a worse prognosis.
Types of ACS 
The spectrum of ACS encompasses 
all clinical syndromes related to acute 
myocardial ischemia as a result of an 
imbalance between the oxygen supply 
and demand in the myocardium.1  As 
mentioned before, the disruption of 
oxygen balance is primarily due to 
diminished myocardial blood flow 
secondary to one or more occlusive 
or partially occlusive coronary artery 
thrombi.  The types of ACS are ST 
segment elevation myocardial infarction 
(STEMI), non-ST segment elevation 
myocardial infarction (NSTEMI), and 
unstable angina (UA).  They are classified 
according to the electrocardiogram (ECG) 
and cardiac chemical biomarkers.  In 
STEMI, the coronary artery thrombus is 
completely occlusive and the ST segment 
on the ECG is elevated.  In both NSTEMI 
and UA, the coronary artery thrombus is 
partially occlusive and the ST segment 
on the ECG is depressed or the T wave is 
inverted.  In order to differentiate between 
NSTEMI from UA, the level of cardiac 
biomarkers of myocardial necrosis such 
as troponin I or T, or creatine kinase 
myocardial band (CK-MB) are obtained 
from a blood test.  NSTEMI differs from 
UA in that the extent of ischemia is 
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usually severe enough to cause myocardial 
necrosis, resulting in the subsequent 
release of biomarkers from the damaged 
tissues into the bloodstream.  Therefore, 
elevated level of cardiac biomarkers is 
often seen in NSTEMI but not in UA.  
Diagnosis & Clinical Presentations
Patients typically present to the 
emergency department with chest pain 
greater than 20 minutes that radiates to 
shoulder, left arm, back, or jaw.1  Atypical 
symptoms that can also be seen in patients 
include nausea and vomiting, diaphoresis, 
and shortness of breath.  These atypical 
symptoms are more common in women, 
diabetics, and the elderly.  A 12-lead 
ECG should be obtained and interpreted 
within 10 minutes of presentation to the 
emergency department with ischemic 
symptoms.  Upon reviewing the findings 
on the ECG, patients are either classified 
as having STEMI or NSTEMI/UA, or 
their complaint may be due to a non-
cardiac issue.  Since myocardial ischemia 
in some parts of the heart may not be 
detected on the surface by the ECG, it is 
important to review the ECG along with 
the cardiac biomarkers.  Following the 
onset of myocardial ischemia, an increase 
in troponin and CK-MB level in the 
blood can be detected.  One set of cardiac 
biomarkers obtained in the emergency 
department is often not long enough to 
detect any changes in the level of the 
cardiac biomarkers.  Therefore, three sets 
of cardiac biomarkers are usually obtained 
6 to 8 hours apart to avoid a false negative 
result.  Further workup and individual 
patient risk assessment should be included 
in the definitive diagnosis of ACS.
ACS Treatment 
Because time is crucial in stopping 
the expansion of infarction and tissue 
death in ACS patients, early treatment 
goals involves timely restoration of blood 
supply to the occluded artery in both 
STEMI and NSTEMI patients, and in 
the case of UA, prevention of complete 
occlusion and MI.1  Other short-term goals 
include symptom relief and prevention of 
other MI complications, recurrent MI, and 
death.
General treatment approaches for 
all STEMI and intermediate to high 
risk NSTEMI or UA patients include 
hospital admission, continuous ECG 
and vital signs monitoring, glycemic 
control, pain relief, and bed rest.1  Upon 
emergency department arrival, MONA 
therapy (see below), and beta-blocker 
therapy if not contraindicated, should be 
initiated immediately for all ACS patients.  
Patients should be triaged by ACS type 
as determined from ECG and laboratory 
findings, after which subsequent treatment 
plan is chosen based on individual 
patient’s signs and symptoms and past 
medical history.
Initial treatment (MONA therapy plus 
Beta-blocker)
Initial treatment of ACS patients 
involves the MONA therapy, which stands 
for Morphine, Oxygen, Nitroglycerin, 
and Aspirin.  Beta-blockers should also 
be given to patients if not contraindicated 
with one or more of the following: 1) signs 
of heart failure, 2) evidence of low cardiac 
output, 3) increased risk of cardiogenic 
shock, 4) second or third degree heart 
block, or 5) active asthma or reactive 
airway disease.2,3  Intravenous morphine 
is administered as an analgesic to patients 
who continue to have  pain refractory to 
nitroglycerin and also acts as a vasodilator 
to reduce preload.  Oxygen is administered 
by nasal cannula to patients with oxygen 
saturation less than 90% for no more 
than 6 hours.  For patients who do not 
appear at risk of hypoxemia or respiratory 
distress, excessive use beyond 6 hours 
can lead to systemic vasoconstriction, 
and high flow rates can be harmful to 
patients with chronic obstructive airway 
disease.2,3  Nitroglycerin is administered 
as continuous IV infusion if patients 
have continued chest pain, and should be 
titrated to pain relief.  However, there are 
contraindications to the use of nitrates 
in patients presenting to emergency 
department with hypotension, marked 
bradycardia or tachycardia, MI in the right 
side of the heart, documented use of a 
phosphodiesterase type 5 inhibitor such as 
sildenafil or vardenafil within 24 hours or 
tadalafil within 48 hours.  Enteric-coated 
aspirin must be chewed and swallowed 
immediately to break the enteric coating 
to achieve rapid platelet inhibition.  
Non-enteric coated formulations may be 
used for more rapid buccal absorption.2,3  
Beta-blockers should be administered 
orally early in hospitalization and continue 
indefinitely to help reduce heart rate, blood 
pressure, and myocardial contractility.  
The use of beta-blocker can reduce the 
risk of recurrent ischemia, infarct size, 
and ventricular arrhythmias following 
MI.  Cardioselective beta-blockers, such 
as metoprolol and atenolol, are commonly 
used, but are not required.  IV beta-
blockers are no longer recommended 
routinely due to a high risk of cardiogenic 
shock.2,3  
Pharmacologic agents for in-hospital 
management of ACS
Once the patients have been stabilized 
with MONA therapy, proper treatment 
for their specific ACS condition needs to 
be initiated.  Drugs used in this process 
include anticoagulants, antiplatelets, 
and fibrinolytics.  We will outline the 
mechanism of action and monitoring 
parameters of these agents prior to 
discussing each agent’s place in therapy.  
Anticoagulant Agents
Anticoagulants essentially inactivate 
clotting factors to prevent thrombus 
formation and extension.2,3  The 
anticoagulant agents that are commonly 
used in the treatment of ACS include 
unfractionated heparin (UFH), enoxaparin, 
fondaparinux, bivalirudin, and warfarin.  
UFH inhibits both factor IIa (thrombin) 
and factor Xa with equal selectivity.2,3  The 
dose is adjusted according to activated 
clotting time (ACT) or activated partial 
thromboplastin time (aPTT), but initial 
dose adjustment for renal or hepatic 
dysfunction is not required.  Some 
contraindications to therapy include active 
bleeding, a history of heparin-induced 
thrombocytopenia (HIT), risk of severe 
bleeding, and recent stroke.  The major 
side effect is bleeding.  When the patient 
is on UFH, the monitoring parameters 
are bedside monitoring of ACT or aPTT, 
platelet count, and signs and symptoms of 
active bleeding.2,3  
Enoxaparin (Lovenox) is a low 
molecular weight heparin (LMWH) 
that inhibits factor Xa more strongly 
than factor IIa.3  Dose reduction is 
required ifcreatinine clearance (CrCl) 
< 30 mL/min, and it is to be avoided 
completely if CrCl < 15 mL/min.  Some 
contraindications include active bleeding, 
history of HIT, risk of severe bleeding, 
and recent stroke.  The major side effects 
are bleeding and bruising.  Monitoring 
parameters for enoxaparin include serum 
creatinine, platelet count, and signs and 
symptoms of bleeding.  An advantage of 
using enoxaparin over UFH is that it can 
be administered subcutaneously.  
Fondaparinux (Arixtra) is a synthetic 
42 • arizona Journal oF Pharmacy • Fall 2013
coNTiNuiNg educaTioN (coNTiNued From Page 41)
pentasaccharide that selectively 
inhibits factor Xa.3  Dose adjustment 
is not required for renal or hepatic 
impairment, but the use of fondaparinux 
is contraindicated if CrCl < 30 mL/min.  
Other contraindications are active bleeding 
and risk of severe bleeding.  Furthermore, 
it has an increased risk of catheter 
thrombosis if used as monotherapy.  
When the patient is on fondaparinux, the 
monitoring parameters include serum 
creatinine and bleeding.  
Bivalirudin (Angiomax) is a direct 
thrombin inhibitor that specifically 
targets thrombin.3  Dose reduction is 
required for severe renal impairment, 
and contraindications are active bleeding 
and risk of severe bleeding.  Also, it has 
an increased risk of stent thrombosis.  
Monitoring parameters include serum 
creatinine and signs and symptoms of 
bleeding.  Bivalirudin monotherapy 
has a lower risk of bleeding than 
the combination therapy of UFH or 
enoxaparin with GP IIb/IIIa inhibitors.  
However, the combination of bivalirudin 
with GP IIb/IIIa inhibitors has a higher 
risk of bleeding without a corresponding 
increase in efficacy, and therefore is not 
recommended to use the combination of 
bivalirudin and GP IIb/IIIa inhibitors.
Warfarin, a vitamin K antagonist, 
reduces thrombus formation by inhibiting 
the activation of vitamin K-dependent 
clotting factors.1  The dose is adjusted 
to maintain a target international 
normalized ratio (INR) of 2 to 3.  Some 
contraindications include active bleeding, 
risk of severe bleeding, pregnancy (except 
in pregnant women with mechanical heart 
valves)and uncontrolled hypertension.  
The major side effect is bleeding.  When 
the patient is on warfarin, the monitoring 
parameters are INR and signs and 
symptoms of bleeding.  Warfarin is not 
commonly used as monotherapy in ACS 
and should be prescribed for patients with 
certain indications for warfarin, such as 
atrial fibrillation, left ventricular thrombus, 
and mechanical prosthetic heart valves.  
Antiplatelet Agents
Aspirin (ASA)
ASA irreversibly inhibits 
cyclooxygenase-1 (COX-1) and COX-2 
enzymes which prevents the formation of 
prostaglandin derivative, thromboxane-A, 
thereby inhibiting platelet aggregation.1  
Dose adjustment is not required for 
renal or hepatic impairment, but avoid 
using ASA if CrCl < 10 mL/min or 
in patient with severe liver disease.  
Some contraindications are active 
bleeding, hemophilia, severe untreated 
hypertension, an active peptic ulcer, or 
another serious source of gastrointestinal 
or genitourinary bleeding.  The major 
side effect is gastrointestinal bleeding.  It 
is the preferred antiplatelet agent in all 
ACS scenarios.  It should be administered 
to patients within 24 hours of hospital 
admission.  The patients will be on ASA 
therapy indefinitely regardless of the type 
of ACS.
Glycoprotein IIb/IIIa Inhibitors
GP IIb/IIIa inhibitors bind to the GP IIb/
IIIa receptors on the platelet preventing 
platelet aggregation and thrombus 
formation.3  The GP IIb/IIIa inhibitors that 
are used in the treatment of ACS include 
abciximab, eptifibitide, and tirofiban.2,3 
Abciximab (ReoPro) does not 
require dose adjustment for renal 
or hepatic impairment.2,3  Some 
contraindications include active bleeding, 
thrombocytopenia, prior stroke and severe 
uncontrolled hypertension.  Abciximab, 
being a monoclonal antibody, has a risk 
of immune-mediated thrombocytopenia, 
which can be treated with platelet 
transfusions as needed for control of 
bleeding.  The major side effect of 
abciximab is bleeding, so the main 
monitoring parameters include signs and 
symptoms of bleeding and platelet counts.  
Eptifibitide (Integrillin) requires 
dose reduction by 50% in patients 
with CrCl < 50mL/min.2,3  Some 
contraindications include active bleeding, 
thrombocytopenia, prior stroke, renal 
dialysis and severe uncontrolled 
hypertension.  Patients can be treated 
with platelet transfusions as needed 
to control bleeding due to a risk of 
thrombocytopenia.  The major side effect 
with eptifibatide is bleeding.  Monitoring 
parameters for this drug include signs and 
symptoms of bleeding, serum creatinine, 
and platelet counts.  
Tirofiban (Aggrastat) requires dose to 
be reduced by 50% in patients with CrCl 
< 30mL/min.2,3  Some contraindications 
are active bleeding, thrombocytopenia, 
prior stroke and severe uncontrolled 
hypertension.  Patients can be treated with 
platelet transfusions as needed to control 
bleeding due to risk of thrombocytopenia.  
The major side effect is bleeding.  
Monitoring parameters for this drug 
include signs and symptoms of bleeding, 
serum creatinine, and platelet counts.  
P2Y12 receptor antagonists 
P2Y12 receptor antagonists block 
the P2Y12 receptors on platelets which 
prevents activation of the GP IIb/IIIa 
receptor complex, thereby reducing 
platelet aggregation.3  The P2Y12 receptor 
antagonists that are used in the treatment 
of ACS include clopidogrel, prasugrel, and 
ticagrelor.2,4
Clopidogrel (Plavix) is the most 
frequently prescribed P2Y12 receptor 
antagonist.  An advantage of clopidogrel 
is that it does not require dose adjustment 
for renal or hepatic impairment.2,3  It 
has a Black Box Warning against its 
use in patients who are poor CYP2C19 
metabolizers.  This is because clopidogrel 
is a prodrug that requires a two-step 
conversion to an active metabolite, and 
the effectiveness of the drug is dependent 
on its activation to an active metabolite by 
CYP2C19.  Poor CYP2C19 metabolism 
results in a smaller antiplatelet effect 
and an increased risk of cardiovascular 
events.  Some contraindications are 
hypersensitivity to clopidogrel, active 
bleeding, and risk of severe bleeding.  The 
major side effect is bleeding.
Prasugrel (Effient) also does not require 
dose adjustment for renal or hepatic 
impairment.2,4  It is also a prodrug, but 
it requires only a one-step conversion to 
active metabolite.  Some contraindications 
with prasugrel include history of transient 
ischemic attack (TIA), stroke, and active 
bleeding.  It has a FDA-labeled warning 
against its use in patients greater than 75 
years old or with a weight less than 60kg 
due to concerns of an increased risk of 
fatal and intracranial bleeding.  Prasugrel 
is most beneficial when used in STEMI 
and diabetic patients.
Ticagrelor (Brilinta) is the most recently 
approved P2Y12 receptor antagonist.  It 
must be administered with a low ASA 
maintenance dose (less than 100mg 
daily).  Some contraindications include 
hypersensitivity to ticagrelor, active 
bleeding, and history of intracranial 
hemorrhage.  Caution should be taken 
in patients when taking ticagrelor with 
CYP3A4 inducers or inhibitors.  The 
major side effects of this drug include 
bleeding and dyspnea.  
Fibrinolytic Agents
Fibrinolytics work by degrading existing 
fibrin clots to open up the blockage in the 
arteries in order to increase blood flow.1  
In NSTEMI/UA patients, fibrinolytic 
therapy is not recommended as clinical 
trials showed no significant benefit 
and an increased risk of MI and death.3  
Fibrinolytic therapy is recommended 
in STEMI patients who do not have 
timely access to a cardiac catheterization 
laboratory.2  Available fibrinolytics 
differ based on their fibrin-specificity; 
streptokinase is non-specific, whereas 
tenectaplase, reteplase and alteplase have 
a higher fibrin-specificity.1 
Streptokinase non-selectively binds 
to either free-flowing or fibrin-bound 
plasminogen and converts it to plasmin.5  
Plasmin is a proteolytic enzyme that 
dissolves the fibrin in the blood clot.  
Dose adjustment is not required for 
renal or hepatic impairment.2  Absolute 
contraindications to fibrinolysis include 
history of hemorrhagic stroke, ischemic 
stroke within 3 months, known malignant 
intracranial neoplasm or arteriovenous 
malformation, active internal bleeding, 
suspected aortic dissection, or significant 
facial or closed head trauma in the last 
3 months.  Relative contraindications 
to fibrinolysis include history of prior 
ischemic stroke more than 3 months 
ago, significant hypertension with blood 
pressure over 180/110 mmHg, recent 
trauma, major surgery within 3 weeks, 
internal bleeding within 2 to 4 weeks, 
oral anticoagulant therapy, active peptic 
ulcer or pregnancy.  The major side 
effect is bleeding.  When the patient is on 
streptokinase, the monitoring parameters 
include performing a complete blood 
count (CBC), aPTT, and watching 
for signs and symptoms of bleeding.  
Streptokinase has a higher risk of 
systemic bleeding than the fibrin-specific 
fibrinolytics.
Tenecteplase, reteplase, and alteplase 
all selectively bind to plasminogens that 
are bound to fibrin and convert them 
to plasmin.5  Dose adjustment is not 
required for renal or hepatic impairment.  
The major side effect for these drugs 
as with all fibrinolytics is bleeding.2  
Contraindications and monitoring 
parameters are the same as non-fibrin-
specific fibrinolytics.  These fibrin-specific 
fibrinolytics have higher risk of ICH than 
streptokinase.  
STEMI Treatment
STEMI patients are at the highest risk 
of death according to the Global Registry 
of Acute Coronary Events (GRACE) 
report, so initial therapy should be 
started immediately for these patients, 
regardless of cardiac biomarkers levels.1  
All STEMI patients should be evaluated 
for reperfusion therapy immediately upon 
arrival at the emergency department.  
Fibrinolytic therapy or primary 
percutaneous coronary intervention 
(PCI) is considered first line treatment 
for restoring coronary artery blood flow 
in STEMI patients.  Primary PCI is 
generally deemed superior to fibrinolytics 
due to lower stroke and bleeding risk, 
lower mortality rate, and higher success 
rate in opening up an occluded coronary 
artery than the latter.  Timing of treatment 
is also crucial to patient survival and 
reducing the extent of damages to the 
infarcted myocardium.  For STEMI 
patients presenting to a hospital with a 
cardiac catheterization laboratory, PCI 
should be performed within 90 minutes of 
initial presentation.2  If the hospital is not 
equipped to perform primary PCI, the next 
treatment choice should be selected based 
on individual patient risks such as the time 
from onset of symptoms, risk of STEMI 
complications, risk of bleeding with 
fibrinolysis, presence of shock or severe 
heart failure, and the time required for 
transfer to a PCI-capable hospital.  Ideally, 
all patients should be transferred to a 
PCI-capable hospital immediately if the 
procedure can be performed within 120 
minutes of first medical contact.  If the 
anticipated time for inter-hospital transfer 
exceeds the target goal, fibrinolytic 
therapy should be chosen as the primary 
reperfusion therapy in the absence 
of contraindications.  If appropriate, 
fibrinolytic agents should be administered 
within 30 minutes of hospital arrival.  
Primary PCI
PCI is a minimally invasive 
revascularization procedure that is 
performed by skilled interventional 
cardiologists in hospitals equipped with 
a cardiac catheterization laboratory.6  
The procedure can be for diagnostic or 
interventional purposes, depending on 
whether revascularization is performed.  
The initial procedure involves cardiac 
catheterization whereby access to coronary 
arteries is commonly obtained through 
the femoral or radial artery up the aorta 
to the suspected occlusion site.  After 
inserting the diagnostic catheter, coronary 
angiography is performed by injecting 
contrast dye into the blood to visualize the 
coronary arteries and determine narrowing 
and blockages of vessels.  If, upon 
examination, an occlusion site is identified 
and revascularization is indicated, balloon 
angioplasty can be performed with the 
help of a guidewire.  Balloon angioplasty 
works by dilating the occluded artery with 
an inflatable balloon, thereby compressing 
the atherosclerotic plaque into the 
vessel wall in order to restore coronary 
perfusion.  Most often, a coronary stent is 
deployed and left in place to prevent acute 
closure of the artery.  Common types of 
stents include bare metal stents (BMS) 
or drug-eluting stents (DES), which are 
coated with an antiproliferative agent 
such as sirolimus or paclitaxel.  The most 
common complication of angioplasty 
is restenosis (i.e.  a renarrowing of a 
previously dilated coronary stenosis).  It 
occurs most frequently in patients with 
angioplasty without stent placement, 
less frequently with BMS, and least 
frequently with DES.  DES implantation 
decreases restenosis rates and the need for 
subsequent target vessel revascularization 
owning to the anti-proliferative effect 
of the coated drugs that helps to retard 
and minimize cell growth.  Despite the 
advantage of DES over BMS, it is also 
associated with a higher risk of stent 
thrombosis, so patients must be adherent 
to dual antiplatelet therapy for one year 
following the procedure.  If patients are 
unable to commit to the dual antiplatelet 
regimen due to factors such as a high 
risk of bleeding, patient incompliance, 
or anticipated invasive or surgical 
procedures in the next year, BMS should 
be considered as an alternative.2  Because 
PCI is an invasive procedure, all patients 
should receive antithrombotic therapy to 
prevent thrombotic complications.  The 
regimen should include antiplatelet agents 
such as ASA, a P2Y12 receptor antagonist, 
and a GP IIb/IIIa inhibitor.  In addition, 
adequate anticoagulation should be 
achieved throughout the duration of the 
procedure to prevent thrombosis of the 
catheter, guidewire, and other thrombotic 
complications.  
ASA should be administered early to 
all patients without contraindications, 
most often included in the MONA therapy 
upon emergency room arrival and within 
24 hours of hospital admission, and 
continued indefinitely after the procedure.2 
High-dose ASA is preferred for patients 
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undergoing primary PCI in order to 
achieve a rapid antiplatelet inhibition.  
If a stent is implanted, patients should 
continue high-dose ASA for a definite 
period of time based on the type of stent 
selected and switch to low-dose ASA 
thereafter.  Low-dose ASA is generally 
recommended for maintenance due to the 
lack of clinical efficacy and risk of major 
bleeding, particularly gastrointestinal 
bleeding, that is associated with high dose 
ASA.  
Since ASA only inhibits platelet 
aggregation through one pathway, it does 
not provide sufficient antiplatelet effect 
when used alone.  Therefore, concomitant 
administration of a P2Y12 receptor 
antagonist, such as clopidogrel, prasugrel, 
or ticagrelor, is recommended.2  In order 
to achieve faster platelet inhibition effects, 
a loading dose should be provided to 
STEMI patients as early as possible or at 
the time of primary PCI.  Following PCI, 
P2Y12 receptor inhibitor therapy should 
be continued on a maintenance dose for at 
least 14 days for patients without a stent 
and up to 1 year for patients with either 
a BMS or DES implanted in the absence 
of bleeding complications.  In general, 
selection of a P2Y12 receptor antagonist 
should be based on patient’s bleeding risk, 
genetic predisposition, comorbidities, and 
additional contraindications for individual 
agent.  Among the P2Y12 inhibitors, 
clopidogrel has the longest history of use 
for treatment of ACS.  Nonetheless, due 
to the pharmacokinetics of clopidogrel, 
patients who carry a certain allele of 
the CYP450 enzyme may have reduced 
capabilities to metabolize the drug, 
leading to significant lower levels of 
active metabolites and diminished platelet 
inhibition.  Consequently, clopidogrel may 
be undesirable for these patients.  Newer 
agents such as prasugrel and ticagrelor 
had demonstrated greater efficacy in 
platelet inhibition and improved patient 
outcome comparing to clopidogrel in 
their corresponding landmark trials, 
namely TRITON-TIMI 38 and PLATO 
respectively.7,8
GP IIb/IIIa inhibitors work on the final 
common pathway of platelet aggregation 
and provide additional platelet inhibition 
when used in combination with other 
antiplatelet agents.  The adjunctive use of 
GP IIb/IIIa inhibitors in STEMI patients 
at the time of PCI should be considered 
on an individual basis and should depend 
on factors such as choice of anticoagulant, 
presence of large thrombus, or inadequate 
P2Y12 receptor inhibitor loading.
2  While 
GP IIb/IIIa inhibitors may be used 
together with either UFH or enoxaparin, 
co-administration with bivalirudin should 
be avoided if possible due to increased 
risk of major bleeding.  If abciximab or 
tirofiban is chosen, a bolus dose should 
be administered prior to continuous IV 
infusion.  For eptifibatide, two boluses 
should be given 10 minutes apart prior 
to continuous IV infusion.  Dosing 
adjustment is required for eptifibatide 
and tirofiban in patients with renal 
dysfunction.  For patients presenting 
with severe renal or hepatic impairment, 
abciximab may be a better alternative 
since no dose adjustment is necessary.  
Following PCI, abciximab can be 
continued for up to 12 hours, eptifibatide 
for 12 to 18 hours, and tirofiban for 
up to 18 hours at the discretion of the 
physician.9  
Anticoagulants that are recommended 
for STEMI patients undergoing primary 
PCI include UFH and bivalirudin.2  
UFH has a long standing history 
of use in STEMI and is the most 
common anticoagulant used in cardiac 
catheterization laboratory.1  One advantage 
of UFH over other anticoagulants is the 
availability of an antidote (i.e.  protamine), 
which is very useful if a reversal of 
anticoagulation is necessary.  Intensity 
of anticoagulation, which can be easily 
monitored at the bedside with ACT, is 
often dependent on whether a GP IIb/
IIIa inhibitor has been administered.  
Additional boluses may be given as 
needed to maintain therapeutic ACT 
levels.  Due to bleeding concerns, 
frequent monitoring is required and is 
often deemed a limitation for its use.  For 
patients with a contraindication for UFH 
or are at high risk of bleeding, bivalirudin 
may be a reasonable alternative to UFH.  
Bivalirudin has been shown to have a 
lower bleeding risk than combination of 
UFH and a GP IIb/IIIa inhibitor, making 
it the preferred agent for STEMI patients 
at high risk of bleeding.2  However, 
bivalirudin has also been associated with 
increased risk of acute stent thrombosis.10  
Since the majority of patients receiving 
PCI have stent placement, bivalirudin 
should be reserved for those with HIT, 
higher risk of bleeding, or when the use 
of GP IIb/IIIa inhibitors is undesirable.2  
Other anticoagulants such as enoxaparin 
and fondaparinux may be used in primary 
PCI in certain ACS settings although 
they are not specifically recommended 
as first line anticoagulants in primary 
PCI.  Enoxaparin may be continued 
uninterrupted during rescue PCI in patients 
who received enoxaparin with prior 
fibrinolytic therapy.2  A supplemental IV 
dose of enoxaparin should be administered 
if the last dose was administered 
between 8 and 12 hours earlier.  After 
12 hours, patients should either receive 
a full dose of enoxaparin or switch to 
UFH or bivalirudin for anticoagulation.  
Fondaparinux should not be used alone 
because it does not provide adequate 
anticoagulation for PCI and is associated 
with higher risk of catheter thrombosis.2  
Therefore, a second anticoagulant like 
UFH or bivalirudin should be administered 
together if fondaparinux is to be selected 
for specific reasons.  Regardless of choice 
of anticoagulant, anticoagulant therapy 
should be discontinued immediately after 
PCI to avoid bleeding complications.  
Fibrinolysis
Fibrinolytic therapy is recommended for 
STEMI patients who are ineligible for PCI 
and present to hospital within 12 hours 
of the onset of chest discomfort.2  This 
time frame has been shown to be most 
beneficial in decreasing the incidence of 
mortality.  For STEMI patients presenting 
to the hospital within 12 to 24 hours 
of symptom onset, fibrinolytic agent 
may be administered if they experience 
ongoing ischemia.  Because fibrinolytic 
agents work by dissolving existing clots, 
patients at high risk of bleeding should 
be assessed for absolute and relative 
contraindications (as described previously) 
prior to administration.1  While 
patients presenting with any absolute 
contraindication are precluded from 
receiving fibrinolytic therapy, patients 
presenting with a relative contraindication 
may still receive treatment if the risk 
of death from MI outweighs the risk of 
major bleeding.  Special consideration 
should be taken in patients over 75 years 
of age.  Although the use of fibrinolytics 
in this age group is not recognized as a 
contraindication, this patient population 
has a higher MI mortality rate associated 
with fibrinolytic use compared to a 
younger patient population.  Therefore, 
careful dosing efforts should be made 
to prevent bleeding when administering 
fibrinolytic and anticoagulation therapies 
to these patients.  In terms of selection of 
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a fibrinolytic agent, fibrin-specific agents 
such as tenecteplase, reteplase, or alteplase 
are preferred over non-fibrin-specific agent 
like streptokinase.  All fibrinolytic agents 
may potentially cause major bleeding 
including intracranial hemorrhage (ICH).
Regardless of the choice of a fibrinolytic 
agent, adjunctive antithrombotic therapy, 
such as anticoagulant and/or antiplatelet 
therapies, should be initiated for STEMI 
patients receiving fibrinolytic therapy.2  
Antiplatelet therapy with fibrinolysis 
includes both ASA and clopidogrel, 
which should be administered before or 
with the fibrinolytic agent.  ASA should 
be continued indefinitely following 
fibrinolytic therapy.  Clopidogrel should 
be continued for at least 14 days and up 
to 1 year based on individual patient’s 
risk of reinfarction.  Currently, prasugrel 
and ticagrelor are not recommended to be 
administered with fibrinolytics because 
these agents have not been studied with 
fibrinolytic therapy.  GP IIb/IIIa inhibitors 
are also not recommended for use with 
fibrinolytics.  Furthermore, patients should 
receive an anticoagulant in addition to 
their fibrinolytic regimen in order to 
minimize vessel obstruction and prevent 
re-occlusion.  Enoxaparin is the preferred 
agent for anticoagulation with fibrinolytic 
therapy.  However, other anticoagulants 
such as UFH and fondaparinux are 
also good alternatives.  The selected 
anticoagulant should be continued for a 
minimum of 48 hours, up to 8 days or 
until revascularization is performed.
In the event of re-occlusion or failed 
reperfusion after fibrinolytic therapy, 
patients may show ongoing ischemic 
symptoms, or worst, develop cardiogenic 
shock or acute severe heart failure.2  These 
patients are at high risk of mortality, and 
are good candidates for a rescue PCI and 
should be transferred to a PCI-capable 
hospital immediately.  If these patients 
have not received a previous loading dose 
of clopidogrel with fibrinolytic therapy, 
a supplemental loading dose should be 
given before or at the time of PCI.  
Coronary Artery Bypass Graft Surgery 
(CABG)
CABG is a surgical alternative to PCI or 
medical management for severe coronary 
artery disease.2  The indications for 
CABG are based on severity of ischemia, 
coronary anatomy, and left ventricular 
function.  In the setting of STEMI, major 
indications for CABG include patients 
with multi-vessel (> 3) disease, significant 
left anterior descending artery stenosis, 
cardiogenic shock, or failed primary 
PCI.11  A number of clinical trials have 
found CABG to be superior to aggressive 
medical management or PCI in the long 
term survival of high risk patients.12,13  The 
surgery is performed by cardiothoracic 
surgeons rather than cardiologists.  During 
the surgical procedure, an artery (internal 
mammary or radial) or vein (usually the 
saphenous) harvested from another part 
of the body is used to form a connection 
between the aorta and the section of the 
coronary artery distal to the occlusion site, 
and consequently, bypassing the occluded 
area and restoring coronary blood flow.14  
Although this type of surgery most often 
requires a cardiopulmonary bypass 
machine, it may be performed “off-pump” 
by skilled cardiac surgeons and can 
significantly reduce serious bleeding and 
thrombotic complications (stroke, MI) 
after the procedure.11
Since CABG is an invasive procedure 
and puts the patients at high risk of 
bleeding, all antiplatelet agents, except 
for ASA, should be withheld before the 
procedure.11  Preoperative ASA use has 
been shown to reduce operative morbidity 
and mortality rates in CABG patients.  In 
contrast, use of P2Y12 receptor antagonists 
is associated with increased rates of 
major bleeding which necessitates blood 
transfusions in post-CABG patients.  
Therefore, patients undergoing urgent 
CABG should discontinue clopidogrel 
and ticagrelor for at least 24 hours prior 
to surgery.  Often, CABG may be an 
elective surgery for certain patients with 
high risk of severe MI.  In these patients 
referred for elective CABG, clopidogrel 
and ticagrelor should be discontinued 
for at least 5 days and prasugrel for at 
least 7 days to decrease major bleeding 
complications.  Other IV antiplatelet 
agents such as eptifibatide and tirofiban 
should be withheld for at least 2 to 4 
hours and abciximab for at least 12 hours 
before surgery to limit blood loss and 
transfusions.  During the surgery, adequate 
anticoagulation should be maintained 
with UFH per institutional practice.3  In 
the absence of contraindications, beta-
blockers should be given 24 hours before 
CABG to decrease the incidence of 
postoperative atrial fibrillation.  Because 
the CABG procedure puts the patient 
at increased risk of developing wound 
or systemic infections, prophylactic 
antibiotics (a first or second generation 
cephalosporin with or without MRSA 
coverage) should be given to all patients.  
In addition, tight postoperative glycemic 
control and lipid management are 
necessary to ensure the best possible 
outcome for all patients.
NSTEMI/UA Treatment 
Invasive vs. Conservative Strategy
Initial treatment of NSTEMI/UA 
involves the use of the Thrombolysis In 
Myocardial Infarction (TIMI) scoring 
system.1  This system calculates the risk of 
composite endpoint of death, MI, or urgent 
need for revascularization within 14 days.  
One point (1) is assigned if the patient has 
each of the following: age greater than 65, 
three or more cardiac risk factors (HTN, 
DM, hyperlipidemia, smoking, family 
history), known history of CAD (greater 
than 50% stenosis seen on angiogram), 
two or more episodes of chest discomfort 
in the last 24 hours, ASA use within the 
last 7 days, elevated cardiac biomarkers, 
and ST-segment deviation on an ECG.  
These criteria are serious risk factors for 
developing either an MI, death, or urgent 
revascularization within the next 14 days.  
Patients presenting with multiple criteria 
should be treated urgently with an invasive 
strategy.  ASA should be initially given to 
NSTEMI/UA patients, with a loading dose 
of clopidogrel, prasugrel, or ticagrelor 
being as a substitute if ASA is intolerant to 
the patient.4
Initial Invasive Strategy
An initial invasive strategy involves 
cardiac catheterization, usually within 4 
to 24 hours following hospital admission, 
followed by either revascularization 
with PCI or CABG.3  This strategy is 
recommended for patients with a moderate 
to high risk of an event according to their 
TIMI score and other high risk features 
such as patients who have refractory 
angina, hemodynamic or electrical 
instability, or initially stabilized NSTEMI/
UA with an elevated risk for clinical 
events.4  Patients with definite NSTEMI/
UA who are at moderate to high risk 
should be given dual antiplatelet therapy 
upon presentation, with ASA being 
one of the agents.3  The choice for the 
second antiplatelet agent can be either 
clopidogrel, prasugrel, ticagrelor, and a GP 
IIb/IIIa inhibitor (tirofiban and eptifibatide 
being the preferred agents).4  These agents 
are to be given either before PCI or at 
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the time of PCI.  This is to reduce the 
risk of ischemic events that may occur 
during PCI, as trauma frequently occurs 
during these types of procedures.  This 
results in platelet activation, aggregation, 
and subsequently a coronary thrombosis.  
Anticoagulants are needed in invasive 
strategies because they limit thrombotic 
complications of ischemic events, 
especially during angioplasty.  They also 
help prevent thrombosis of catheters and 
guidewires used during these procedures.  
Depending on the results of the diagnostic 
angiography, there are three possible post-
angiography management strategies one 
can initiate, depending on the findings of 
the angiography: CABG, PCI, or medical 
therapy.3 
CABG
CABG surgery is strongly 
recommended in NSTEMI/UA patients 
with significant left main coronary artery 
disease (CAD), 3-vessel disease, 2-vessel 
disease, or when PCI is not optimal or 
possible.11  If CABG is selected, continue 
ASA therapy; discontinue clopidogrel 
for least 5 days, prasugrel for at least 7 
days, and ticagrelor for at least 5 days 
prior to CABG procedure.4  ASA  is used 
to provide antiplatelet therapy during the 
procedure, while the other antiplatelets 
are discontinued as they incur a serious 
risk of bleeding.3  Prasugrel has an earlier 
discontinuation time than clopidogrel 
and ticagrelor because it has a much 
higher risk of bleeding than those two 
agents.  Intravenous GP IIb/IIIa inhibitors 
(eptifibatide and tirofiban) must also be 
discontinued 2 – 4 hours prior to CABG 
procedure.  UFH is to be continued, while 
enoxaparin must be discontinued 12 to 
14 hours, fondaparinux 24 hours, and 
bivalirudin 3 hours prior to CABG.  
PCI
PCI is recommended for NSTEMI/UA 
patients with 1- or 2- vessel CAD and 
multi-vessel coronary disease with suitable 
coronary anatomy.3  If PCI is selected, 
ASA is to be continued.  A loading dose 
of clopidogrel, prasugrel, or ticagrelor, 
and/or GP IIb/IIIa should be given if 
not given prior to angiography.4  GP IIb/
IIIa inhibitors are highly recommended 
in addition to ASA and P2Y12 inhibitors 
in PCI patients to reduce morbidity and 
mortality based on several randomized 
control trials.  A study involving 
abxicimab or placebo given to patients 
showed that the patient group receiving 
abxicimab in addition to clopidogrel 
showed a significant reduction in the 
primary end points of death, nonfatal 
reinfarction, or urgent target-vessel 
vascularization within 30 days.15  Once 
PCI is completed, anticoagulant therapy 
can be discontinued.3 
Medical Therapy
Medical therapy is recommended for 
post-angiographic NSTEMI/UA patients 
with no signs of significant obstructive 
CAD on angiography.4  Antiplatelet and 
anticoagulant therapy is used in these 
patients at a physician’s discretion.  If 
CAD is detected on angiography, ASA 
should be continued.3  A loading dose of 
clopidogrel or ticagrelor should be given 
to provide a rapid antiplatelet effect if not 
given prior to angiogram, as maintenance 
doses require a few days to achieve full 
effect.  Prasugrel is not recommended 
because it has only proven benefit in 
patients undergoing PCI.  IV GP IIb/
IIIa inhibitors should be discontinued 
after at least 12 hours if it was started 
before the angiogram.  IV UFH should 
be continued for at least 48 hours or 
enoxaparin or fondaparinux for the 
duration of hospitalization, up to 8 days.  
Bivalirudin can be continued at a dose 
of 0.25 mg/kg/hr for up to 72 hours at a 
physician’s discretion if it was given prior 
to diagnostic angiography.
Initial Conservative Strategy
An initial conservative treatment 
strategy is recommended for NSTEMI/
UA patients with a low stratified TIMI risk 
score.4  This treatment strategy involves 
initial medical management, followed by 
catheterization and revascularization if 
an ischemic event occurs despite active 
drug treatment.  Patients presenting with 
a low risk of death, MI (either initial or 
recurrent), or refractory angina are usually 
evaluated in the emergency department.  
Serum biomarkers are obtained from the 
patient, and if they are negative for these 
biomarkers, the patient may be directed 
to a general medical area to undergo ECG 
monitoring for any ischemic events or 
arrhythmias.  In addition, a stress test, 
such as an exercise stress test, can be 
performed.  If there are positive findings 
in the stress test, diagnostic angiography 
should be performed.
For these low risk patients, ASA should 
be initially given, along with either 
clopidogrel or ticagrelor (loading dose 
followed by daily maintenance doses) 
as soon as possible after admission.4  
ASA is to be continued indefinitely 
while clopidogrel or ticagrelor should 
be continued for one month and up to 12 
months.  If the patient is stable and their 
symptoms are controlled, they can be 
discharged with recommended antiplatelet 
therapy such as clopidogrel or ticagrelor 
for a duration ranging from one month to 
one year.  
If an ischemic event does occur 
while the patient is on drug therapy, 
an angiography should be performed, 
and invasive strategies (CABG, PCI, or 
medical therapy for CAD) are initiated.4  
Prior to angiography, either an IV GP IIa/
IIIb inhibitor (tirofiban or eptifibatide) 
or a P2Y12 inhibitor (clopidogrel or 
ticagrelor, loading dose followed by daily 
maintenance doses) should be added to 
ASA and anticoagulant therapy.
Discharge Medications and Secondary 
Prevention 
Once a patient has received appropriate 
treatment for ACS and is recovering, it is 
imperative that they be put on appropriate 
medications for secondary prevention of 
ischemic events prior to discharge.1  ACS 
patients should be on ASA indefinitely, 
in addition to a beta-blocker and statin 
therapy.  ASA has been shown in a large 
number of clinical trials to decrease the 
risk of death, recurrent MI, and stroke 
following an MI.3  If the patient is unable 
to take ASA due to contraindications, 
clopidogrel is recommended.  All patients 
should be given sublingual nitroglycerin 
(SL NTG) tablets or a lingual nitroglycerin 
spray in the event if they experience 
recurrent chest pain and discomfort.  Beta-
blockers are recommended indefinitely 
because they have been shown to decrease 
the incidence of recurrent MI.  However, 
they are contraindicated in HF patients 
with acute decompensation.  ACE 
inhibitors are indicated in patients who 
are not at blood pressure goals on beta-
blocker therapy, as well as patients with 
a reduced ejection fraction or diabetic 
patients.  Angiotensin II receptor blockers 
can be given if the patient suffers from 
ACE inhibitor induced angioedema.  
According to ACC/AHA guidelines, the 
goal blood pressure for HTN patients with 
ACS is 130/80 mmHg.  In addition, it is 
imperative that ACS patients receive lipid-
lowering agents such as statins, as they are 
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used to prevent total mortality and stroke.  
Furthermore, all ACS patients should be 
provided appropriate pharmacological and 
non-pharmacological therapy to achieve a 
goal LDL level of less than 100 mg/dL.  
Other modifiable risk factors such as 
diabetes mellitus and smoking are also 
important in secondary prevention of 
ACS.  According to ADA guidelines, the 
goal HgB A1c level for ACS patients with 
diabetes is < 7%.  Smoking cessation is 
correlated with a significant reduction in 
all-cause mortality in all ACS patients, and 
can be achieved by various products such 
as varenicline or nicotine patches/gums.  
Proper diet and exercise is also important, 
as maintaining an ideal weight is essential 
in preventing the reoccurrence of ACS 
events.
In certain patients with atrial fibrillation 
with a CHADS2 score of greater 
than or equal to 2, mechanical heart 
valves, venous thromboembolism, or a 
hypercoagulable disorder, warfarin may be 
indicated.2  Co-administration of warfarin 
and dual antiplatelet therapy may put 
patients at high risk of severe bleeding.  
Therefore, the duration of use should be 
limited to the extent of anticoagulation 
deemed necessary.  A lower INR goal (2.0 
– 2.5) should also be considered.
Conclusions
Acute coronary syndromes contribute 
to a significant number of cardiovascular 
related deaths in the US.1  Pharmacists 
have an important role in managing 
the disease state for the patient from 
the beginning in the emergency room 
to discharging the patients from the 
hospital.  Pharmacists need to be vigilant 
in selecting the most appropriate therapy 
for their patients based on the type of 
ACS and patient specific factors in order 
to help reduce the risk of developing side 
effects and complications, re-infarction, 
and most importantly, death.  Pharmacists 
are an integral part of the health care team 
that can provide dosing and monitoring 
recommendations for medications, as well 
as provide education to patients to prevent 
recurrent cardiac events.
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Score Composite endpoint of MI, death, or urgent revascularization Risk 
0 - 1 4.7% 
Low 
2 8.3% 
3 13.2% 
Moderate 
4 19.9% 
5 26.2% 
High 
6 - 7 40.9% 
 
Source: Adapted from information found in reference 1 
 
 
 
 
 
 Agents Goals of Therapy 
Blood Pressure Beta-blocker (BB) 
 
Non-DHP CCB (if intolerant to BB) 
 
ACE inhibitors (ACEi) 
 
Aldosterone Antagonists (AA) 
< 130/80 mmHg  
 
ACEi and AA if LVEF < 40% 
Lipid Management Statins LDL < 100 mg/dL 
Diabetes Various HgB A1c < 7% (ADA Guidelines) 
Smoking Cessation Various No smoking 
BMI Exercise 5-7 times/week 18.5 – 24.9 kg/m2 
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ST-elevation myocardial infarction (STEMI) 
 Drug Procedure[ACC/AHA 
Guideline 
Recommendations] 
Dose 
Adjustment 
Warnings / DDI/ 
Contraindications* 
Monitoring Dose and Duration of Therapy 
An
tip
la
te
le
ts
 
Aspirin 
(ASA) 
Initial treatment after 
hospital admission 
[IB] 
No  Hypersensitivity 
 Active bleeding 
 Risk of severe 
bleeding 
 Bleeding  162-325 mg before PCI, then 81 mg 
maintenance dose daily indefinitely 
 If a stent is placed after PCI, continue 
162-325 mg daily 
- for a minimum of 30 days (bare metal 
stent) 
- for 3 months (sirolimus-eluting stent) 
- for 6 months (paclitaxel-eluting stent) 
- then continue 75-162 mg daily 
indefinitely 
Abciximab 
{Reopro®} 
PCI [IIa, A] No  Active bleeding* 
 Thombocytopenia* 
 Prior stroke ≤ 2 
years* 
 SCr 
 Platelet count 
 Bleeding 
 0.25 mg/kg IV bolus, then 0.125 
mcg/kg/min IV infusion 
 Continue for up to 12 hr  
Eptifibatide 
{Integrilin®} 
PCI [IIa, B] CrCl <50 
mL/min: 
reduce 
infusion 50% 
 Active bleeding* 
 Prior stroke ≤ 30 
days* 
 Renal dialysis* 
 Thombocytopenia 
 SCr 
 Platelet count 
 Bleeding 
 180 mcg/kg IV bolus x 2, then 2 
mcg/kg/min IV infusion 
 Continue for 12 – 18 hr after PCI 
Tirofiban 
{Aggrastat®} 
PCI [IIa, B] CrCl <30 
mL/min: 
reduce 
infusion 50%  
 Active bleeding* 
 Thombocytopenia* 
 Prior hemorrhagic 
stroke* 
 SCr 
 Platelet count 
 Bleeding 
 25 mcg/kg IV bolus, then 0.15 
mcg/kg/min IV infusion 
 Continue for 18 hr after PCI 
Clopidogrel 
{Plavix®} 
Fibrinolytic [IA] No  Hypersensitivity 
 Active bleeding* 
 Risk of severe 
bleeding 
 Reduced 2C19 
function (BBW) 
 Caution with 2C19 
inhibitors 
 Hold 5 days prior 
to CABG surgery 
 SCr 
 Bleeding 
 < 75 y.o.: 300 mg PO loading dose, then 
75 mg   
                  daily maintenance dose  
> 75 y.o.: 75 mg daily 
 Continue for 14 days to 1 year in 
absence of bleeding 
PCI [IB]  300 mg (PCI ≤ 24 hr) or 600 mg (PCI > 24 
hr) PO loading dose, then 75 mg PO 
daily maintenance dose 
 Continue for 14 days if no stent is 
placed or 1 year if either a BMS or DES 
is placed 
Prasugrel 
{Effient®} 
PCI [IB] No  Active bleeding* 
 History of TIA or 
stroke (BBW) 
 Age > 75 y.o.(BBW) 
 Weight < 60 kg 
(BBW) 
 Hold 7 days prior 
to CABG surgery 
 SCr 
 Bleeding 
 60 mg PO loading dose, then 10 mg PO 
daily maintenance dose 
 Continue for 14 days if no stent is 
placed or 1 year if either a BMS or DES 
is placed 
 
Ticagrelor 
{Brilinta®} 
PCI [IB] No  Hypersensitivity 
 Active bleeding* 
 History of ICH 
(BBW) 
 Must use with low 
dose aspirin (BBW) 
 Caution with 3A4 
inducers/ inhibitors 
 Hold 5 days prior 
to CABG surgery 
 SCr 
 Bleeding 
 180 mg PO loading dose, then 90 mg PO 
twice a day maintenance dose 
 Continue for 14 days if no stent is 
placed or 1 year if either a BMS or DES 
is placed 
 
 
 
 
ST-elevation myocardial infarction (STEMI) 
 Drug Procedure[ACC/AHA 
Guideline 
Recommendations] 
Dose 
Adjustment 
Warnings / DDI/ 
Contraindications* 
Monitoring Dose and Duration of Therapy 
Fi
br
in
ol
yt
ic
s 
Alteplase (tPA) 
{Activase®} 
Fibrinolytic therapy ≤ 
30 min of hospital 
arrival [IB] 
No 
 
 Prior ICH* 
 Known structural 
cerebrovascular 
lesions, such as 
arterial venous 
malformation* 
 Known intracranial 
malignant 
neoplasm* 
 Ischemic stroke ≤ 3 
months* 
 Active bleeding* 
(excluding menses) 
 Significant closed 
head or facial 
trauma ≤ 3 
months* 
 CBC 
 aPTT 
 Bleeding 
 15 mg IV bolus, followed by 0.75 mg/kg 
IV (max 50 mg) over 30 min, then 0.5 
mg/kg (max 35 mg) over 60 min (max 
dose = 100 mg)  
Reteplase (rPA) 
{Retavase®} 
 
Fibrinolytic therapy ≤ 
30 min of hospital 
arrival [IB] 
 10 unit IV x 2, 30 min apart 
Tenecteplase 
(TNK-tPA) 
{Tnkase®} 
Fibrinolytic therapy ≤ 
30 min of hospital 
arrival [IB] 
 < 60 kg: 30 mg IV bolus 
60 – 69 kg: 35 mg IV bolus 
70 – 79 kg: 40 mg IV bolus 
80 – 89 kg: 45 mg IV bolus 
> 90 kg: 50 mg IV bolus 
Streptokinase 
{Streptase®} 
Fibrinolytic therapy ≤ 
30 min of hospital 
arrival [IB] 
 1.5 MU (million units) IV over 60 min 
An
tic
oa
gu
la
nt
s 
Unfractionated 
Heparin (UFH) 
Fibrinolytic therapy 
[IC] 
No  Active bleeding* 
 History of HIT* 
 Risk of severe 
bleeding 
 Recent stroke  
 aPTT: 50 – 70 
sec 
 ACT: 200-300 
sec (with GPI); 
250-350 sec 
(no GPI) 
 HIT 
 Bleeding 
 60 units/kg IV bolus, then 12 units/kg/hr 
IV infusion 
 Continue for 48 hours 
PCI [IC]  With GPI: 50-70 units/kg IV bolus  
    No GPI: 70-100 units/kg IV bolus 
 Discontinue at the end of PCI 
Enoxaparin 
(LMWH) 
{Lovenox®} 
Fibrinolytic therapy 
[IA] 
Reduce if 
CrCl < 30 
mL/min 
 Active bleeding* 
 History of HIT 
 Risk of severe 
bleeding 
 Recent stroke 
 Avoid if CrCl < 15 
mL/min 
 Avoid if CABG 
surgery 
 SCr 
 HIT 
 Bleeding 
 < 75 y.o.: 30 mg IV bolus, then 1mg/kg 
SC every 12 hr 
   > 75 y.o.: 0.75 mg/kg SC every 12 hr 
 Continue for the duration of 
hospitalization (up to 8 days) 
PCI after fibrinolytic 
therapy [IB] 
 1 mg/kg SC every 12 hours (if last dose > 
8 hours prior to PCI, administer 0.3 
mg/kg IV bolus) 
 Discontinue at the end of PCI 
Fondaparinux 
{Arixtra®} 
Fibrinolytic therapy 
[IB] 
No  Active bleeding* 
 Risk of severe 
bleeding 
 Avoid if CrCl < 30 
mL/min 
 Increase risk of 
catheter 
thrombosis if used 
as monotherapy 
 SCr 
 Bleeding 
 2.5 mg IV, then 2.5 mg SC daily 
 Continue for the duration of 
hospitalization (up to 8 days) 
PCI [III, B]  
*not as 
monotherapy* 
 
 2.5 mg IV, then 2.5 mg SC daily (MUST 
administer UFH 50-60 units/kg IV bolus 
prior) 
 Discontinue at the end of PCI 
Bivalirudin 
{Angiomax®} 
PCI [IB] 
*can be used in place 
of UFH + GPI if high 
risk of bl eding  
[IIa, B]* 
Severe renal 
function 
 Active bleeding* 
 Risk of severe 
bleeding 
 I crease risk of 
stent thrombosis 
 SCr 
 Bleeding 
 0.75 mg /kg IV bolus, then 1.75 
mg/kg/hr IV 
 Discontin e at the end of PCI 
Table for Continuing Education 
Article - Acute Coronary 
Syndromes: Current Treatment 
guidelines and Updates
Source: Adapted from 
information found in references 
1,2,11,16.
DDI indicates drug-drug 
interaction; ICH, intracranial 
hemorrhage; CBC, complete 
blood count; aPTT, activated 
partial thromboplastin time; HIT, 
heparin-induced thrombocytopenia; 
ACT, activated clotting time; GPI, 
glycoprotein IIb/IIIa inhibitor; IV, 
intravenous; PCI, percutaneous 
coronary intervention; LMWH, 
low molecular weight heparin; SCr, 
serum creatinine; CrCl, creatinine 
clearance; SC, subcutaneous; 
CABG, coronary artery bypass 
graft; BBW, black box warning; 
PO, per os (by mouth); BMS, bare 
metal stent; DES, drug eluting 
stent. 
Full article, including charts, is 
available for download on the AzPA 
website in the Journal archives.
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 Non-ST elevation myocardial infarction (NSTEMI) / Unstable angina (UA) 
 Drug Procedure[ACC/AHA 
Guideline 
Recommendations] 
Dose 
Adjustment 
Warnings / DDI/ 
Contraindications*  
Monitoring Dose and Duration of Therapy 
An
tip
la
te
le
ts
 
Aspirin (ASA) Initial treatment after 
hospital admission 
[IA] 
No  Hypersensitivity 
 Active bleeding 
 Risk of severe bleeding 
 Bleeding  162-325 mg before procedure, 
then 81 mg maintenance dose 
daily indefinitely 
 If a stent is placed after PCI, 
continue 162-325 mg daily 
- for at least 30 days (bare metal 
stent) 
- for 3 months (sirolimus-eluting 
stent) 
- for 6 months (paclitaxel-eluting 
stent) 
- then continue 75-162 mg daily 
indefinitely 
Abciximab 
{Reopro®} 
Invasive strategy: 
 PCI [IA] 
No  Active bleeding* 
 Thombocytopenia* 
 Prior stroke ≤ 2 years* 
 SCr 
 Platelet 
count 
 Bleeding 
 0.25 mg/kg IV bolus, then 0.125 
mcg/kg/min IV infusion 
 Continue for up to 12 hr after PCI 
Eptifibatide 
{Integrilin®} 
Invasive strategy: 
 Before PCI [1B] 
 PCI [IA] 
CrCl <50 
mL/min: 
reduce 
infusion 50% 
 Active bleeding* 
 Prior stroke ≤ 30 days* 
 Renal dialysis* 
 Thombocytopenia 
 SCr 
 Platelet 
count 
 Bleeding 
 180 mcg/kg IV bolus x 2 (10 min 
apart), then 2 mcg/kg/min IV 
infusion 
 Continue for 12 – 18 hr after PCI 
Conservative strategy: 
 Before angiography 
[IIb, B] 
 Angiography [IA] 
 180 mcg/kg IV bolus, then 2 
mcg/kg/min IV infusion 
 If no angiography, discontinue 
 If angiography, continue for up to 
72 hr 
Tirofiban 
{Aggrastat®} 
Invasive strategy: 
 Before PCI [1B] 
 PCI [IA] 
CrCl <30 
mL/min: 
reduce 
infusion 50%  
 Active bleeding* 
 Thombocytopenia* 
 Prior stroke ≤ 2 years* 
 SCr 
 Platelet 
count 
 Bleeding 
 25 mcg/kg IV bolus, then 0.15 
mcg/kg/min IV infusion 
 Continue for up to 18 hr after PCI 
Conservative strategy: 
 Before angiography 
[IIb, B] 
 Angiography [IA] 
 50 mcg/mL administered at a 
rate of 0.4 mcg/kg/min over 30 
min, then 0.1 mcg/kg/min IV 
infusion  
 If no angiography, discontinue 
 If angiography, continue for up to 
72 hr 
Clopidogrel 
{Plavix®} 
Invasive strategy: 
 Before PCI [1B] 
 PCI [IA] 
 
No  Hypersensitivity 
 Active bleeding* 
 Risk of severe bleeding 
 Reduced 2C19 function 
(BBW) 
 Caution with 2C19 
inhibitors 
 Hold 5 days prior to 
CABG surgery 
 SCr 
 Bleeding 
 300 – 600 mg PO loading dose, 
then 75 mg PO daily maintenance 
dose  
 If PCI, continue for at least 12 
months. 
 If no PCI, continue for up to 12 
months  
Conservative strategy: 
 Before angiography 
[IB] 
 Angiography [IB] 
Prasugrel 
{Effient®} 
Invasive strategy: 
 PCI [IB] 
 
No  Active bleeding* 
 History of TIA or stroke 
(BBW) 
 Age > 75 y.o.(BBW) 
 Weight < 60 kg (BBW) 
 Hold 7 days prior to 
CABG surgery 
 SCr 
 Bleeding 
 60 mg PO loading dose, then 10 
mg PO daily maintenance dose  
 Continue for up to 12 months 
 
Ticagrelor 
{Brilinta®} 
Invasive: 
 Before PCI [1B] 
 PCI [IB] 
 
No  Hypersensitivity 
 Active bleeding* 
 History of ICH (BBW) 
 Must use with low dose 
aspirin (BBW) 
 Caution: 3A4 inducers/ 
inhibitors 
 Hold 5 days prior to 
CABG surgery 
 SCr 
 Bleeding 
 180 mg PO loading dose, then 90 
mg PO daily maintenance dose  
 If PCI, continue for at least 12 
months 
 If no PCI, continue for up to 12 
months 
Conservative strategy: 
 No angiography [IB] 
 Angiography [IB] 
 
 Non-ST elevation myocardial infarction (NSTEMI) / Unstable angina (UA) 
 Drug Procedure[ACC/AHA 
Guideline 
Recommendations] 
Dose 
Adjustment 
Warnings / DDI/ 
Contraindications*  
Monitoring Dose and Duration of Therapy 
An
tic
oa
gu
la
nt
s 
Unfractionated 
Heparin (UFH) 
Invasive strategy: 
 Before PCI [IA] 
 PCI [IA] 
 
No  Active bleeding* 
 History of HIT* 
 Risk of severe bleeding 
 Recent stroke  
 aPTT: 50 – 
70 sec 
 ACT:  200-
300 sec 
(with GPI); 
250-350 
sec (no 
GPI) 
 HIT 
 Bleeding 
 60 units/kg IV bolus, then 12 
units/kg/hr IV infusion 
 Continue for 48 hr or discontinue 
at the end of PCI  
Conservative strategy  
[IA] 
 60 units/kg IV bolus, then 12 
units/kg/hr IV infusion 
 Continue for 48 hr or until 
discharge 
Enoxaparin (LMWH) 
{Lovenox®} 
Invasive strategy: 
 Before PCI [IA] 
 PCI [IA] 
Reduce if 
CrCl < 30 
mL/min 
 Active bleeding* 
 History of HIT 
 Risk of severe bleeding 
 Recent stroke 
 Avoid if CrCl < 15 
mL/min 
 Avoid if CABG surgery 
(discontinue 12-24 hrs 
prior) 
 SCr 
 HIT 
 Bleeding 
 1 mg/kg SC every 12 hours (if last 
dose > 8 hours prior to PCI, 
administer 0.3 mg/kg IV bolus) 
 Discontinue at the end of PCI 
Conservative strategy 
[IA] 
 1 mg/kg SC every 12 hours  
 Continue for the duration of 
hospitalization (up to 8 days) 
Fondaparinux 
{Arixtra®} 
Invasive strategy: 
 Before PCI [IB] 
 PCI [III,C] 
*not as 
monotherapy* 
No  Active bleeding* 
 Risk of severe bleeding 
 Avoid if CrCl < 30 
mL/min 
 Avoid if CABG surgery 
(discontinue 24 hrs 
prior) 
 Increase risk of catheter 
thrombosis if used as 
monotherapy 
 SCr 
 Bleeding 
 2.5 mg SC daily (MUST administer 
UFH 50-60 units/kg IV bolus 
prior) 
 Discontinue at the end of PCI 
Conservative strategy 
[IB] 
 2.5 mg SC daily 
 Continue for the duration of 
hospitalization (up to 8 days) 
Bivalirudin 
{Angiomax®} 
Invasive strategy: 
 Before PCI [IB] 
 PCI [IB] 
*can be used if high 
risk of bleeding* 
Severe renal 
function 
 Active bleeding* 
 Risk of severe bleeding 
 Avoid if CABG surgery 
(discontinue 3 hrs prior) 
 Increase risk of stent 
thrombosis 
 SCr 
 Bleeding 
 Before PCI, 0.1 mg/kg IV bolus, 
then 0.25 mg/kg/hr IV infusion 
 If given before PCI, 0.5 mg/kg IV 
bolus, then 1.75 mg/kg/hr IV 
infusion 
 If not given before PCI, 0.75 
mg/kg IV bolus, then 1.75 
mg/kg/hr IV infusion 
 Discontinue at the end of PCI  
Conservative strategy:  
 Angiography [IB] 
 Before angiography, 0.1 mg/kg IV 
bolus, then 0.25 mg/kg/hr IV 
infusion 
 Discontinue at the end of 
angiography or continue at 0.25 
mg/kg/hr for up to 72 hr if 
prolonged anticoagulation 
necessary 
Table for Continuing Education 
Article - Acute Coronary 
Syndromes: Current Treatment 
guidelines and Updates 
Source: Adapted from 
information found in references 
1,3,4,11.
DDI indicates drug-drug 
interaction; ICH, intracranial 
hemorrhage; aPTT, activated 
partial thromboplastin time; HIT, 
heparin-induced thrombocytopenia; 
ACT, activated clotting time; GPI, 
glycoprotein IIb/IIIa inhibitor; IV, 
intravenous; PCI, percutaneous 
coronary intervention; LMWH, 
low molecular weight heparin; SCr, 
serum creatinine; CrCl, creatinine 
clearance; SC, subcutaneous; 
CABG, coronary artery bypass 
graft; BBW, black box warning; 
PO, per os (by mouth).
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coNTiNuiNg educaTioN Quiz QuesTioNs
1.  A 72-year old female presents to the 
hospital for chest pain that started about 11 
hours ago, but has been getting worse in 
the last 30 minutes.  Her EKG reveals ST-
segment depression and T- wave inversions.  
Her first two set of cardiac biomarkers reveals 
elevated CK-MB and troponins.  Which of the 
following is the most likely diagnosis?
a.  NSTEMI         
b.  STEMI
c.  Unstable angina
d.  Non-cardiac cause of chest pain
e.  Cannot determine based on the information 
given
2.  A 68-year old female patient presents to 
the hospital with crushing chest pain that 
started 30 minutes ago.  She has received 3 
doses of sublingual nitroglycerin, but has 
been getting worse in the last 15 minutes. 
According to her past medical history, she 
has asthma and heart failure (left ventricular 
ejection fraction 10-15%).  Her vital: BP 
156/92,  HR 72, O2 saturation on room air 
79%.  Which of the following is the BEST 
recommendation for this patient?
a.  Chew aspirin 325 mg, titrate oxygen to 
100% O2 saturation, nitroglycerin 0.4 mg SL, 
metoprolol 25 mg IV 
b.  Chew aspirin 325 mg, titrate oxygen to 
100% O2 saturation, nitroglycerin 0.4 mg SL,  
metoprolol 25 mg PO
c.  Chew aspirin 325 mg, morphine 2 mg IV, 
and titrate oxygen to 100% O2 saturation 
d.  Chew aspirin 325 mg. morphine 2 mg 
IV, titrate oxygen to 100% O2 saturation, 
metoprolol 25 mg IV
e.  Chew aspirin 325 mg. morphine 2 mg 
IV, titrate oxygen to 100% O2 saturation, 
metoprolol 25 mg PO
3.  TG is a 60 year old female that was 
presented to the emergency room with 
complaints of throbbing chest pain.  She was 
initially given 3 SL tablets of NTG in the last 
15 minutes, however she is still having chest 
pain. Her O2 sats are at 86%.  Her LVEF is 
at 30% according to TTE.  What medications 
and or therapy should this patient being 
receiving next?
a.  Initial invasive strategy with preference 
for PCI
b.  IV morphine + ASA
c.  IV morphine + oxygen administered via 
nasal cannula + ASA
d.  Patient does not need anything, as this not 
an ACS case
4.  BN is an 80 year old male who develops 
crushing chest pain that started 30 minutes 
ago.  The EKG in the ambulance reveals 
that the patient is having a STEMI.  The 
nearest hospital with a cardiac catheterization 
laboratory is three hours away.  What is the 
most appropriate initial treatment strategy for 
this patient?
a.  Transfer directly to hospital with 
catheterization laboratory for PCI
b.  Admit to nearest hospital for fibrinolytic 
therapy
c.  Admit to nearest hospital for diagnostic 
stress test
d.  Admit to nearest hospital for CABG
5.  JT is a 75 year old male who presents to 
the emergency department with complaints of 
chest pain.  He states that he has 3 episodes of 
chest pain in the past 24 hours.  In addition, 
he has a history of coronary artery disease, 
as well at hypertension and diabetes.  A 
preliminary ECG shows sinus tachycardia. 
What is his risk assessment based on his TIMI 
score?
a.  Low risk         b.  Moderate risk
c.  High risk         d.  No risk
6.  YU has been diagnosed with having 
NSTEMI because on his ECG readings and 
cardiac biomarkers.  Based on his TIMI score 
and risk assessment, he is stratified as being 
moderate risk.  What initial strategy should 
YU undergo for treatment of his NSTEMI?
a.  Invasive strategy
b.  Conservative strategy
c.  No further therapy is needed 
d.  More information is needed
7.  Which of the following laboratory values 
should be monitored for a patient treated with 
abciximab?
a.  Serum creatinine
b.  Liver function tests
c.  Platelets
d.  Troponin
8.  Which of the following describes an 
advantage of UFH over other anticoagulants 
used in ACS patients?
a.  Lower incidence of heparin-induced 
thrombocytopenia
b.  Can be monitored in catheterization lab 
with ACT
c.  Administration routes include 
subcutaneously or intravenously
d.  Lower incidence of bleeding compared to 
bivalirudin
9. Which of the following is an absolute 
contraindication to fibrinolytic therapy?
a.  Ischemic stroke within the last 3 months
b.  Blood pressure greater than 180/110 mmHg
c.  Chronic warfarin therapy
d.  Pregnancy
10.  A 45 year old male patient weighing 120 
kg was admitted to the hospital and diagnosed 
with having STEMI.  He has a history of 
recent gastrointestinal bleeding and is currently 
taking omeprazole for it.  Which antiplatelet 
medication would be best given to initially 
treat this patient for his STEMI?
a.  ASA          b.  ASA + clopidogrel
c.  ASA + prasugrel        d.  ASA + ticagrelor
e.  None of the above
11.  LK is an 80 year old male with a history 
of COPD.  He is afraid taking medications that 
may exacerbate his COPD.  He was admitted 
to the hospital and was diagnosed with having 
STEMI. A PCI was performed and a sirolimus 
stent was implanted in his coronary artery.  
What medication regimen is appropriate for 
this patient upon discharge for maintenance of 
his ACS?
a.  ASA 325mg daily for 1 months + 
clopidogrel 75mg daily for 2 months
b.  ASA 325 mg daily for 3 months + ticagrelor 
90mg BID for 12 months
c.  ASA 325 mg daily for 3 months + prasugrel 
10 mg daily for 12 months
d.  ASA 325 mg daily for 3 months + 
clopidogrel 300mg daily for 12 months
e.  ASA 325 mg daily for 3 months + prasugrel 
10 mg daily for 3 months
12.  A 57 year old male patient who is currently 
on eptifibatide, prasugrel, and unfractionated 
heparin is about to undergo elective CABG for 
his NSTEMI. Which of the following changes 
in his drug are appropriate to make prior to his 
upcoming procedure?
a.  Hold the UFH for at least 2 days
b.  Hold the prasugrel for at least 5 days
c.  Hold the prasugrel for at least 7 days
d.  Hold the eptifibatide for at least 2 hours
e.  c and d
13.  HT is a 50 year old male patient that was 
recently treated at the hospital for his STEMI 
and is ready to be discharged.  His past medical 
history includes hypertension and type 2 
diabetes.  What medications should HT be 
placed on prior to him being discharged for 
secondary prevention of ACS?
a.  Atorvastatin 
b.  Aspirin
c.  Metoprolol
d.  b and c
e.  All of the above
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ANSwER SHEET AND EVALUATION FOR 
THIS HOME-STUDY ACTIVITY ARE ON  
PAgE 50.
